Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
Purpose of Review
Chimeric antigen receptor (CAR) T cells are a form of adoptive therapy employing autologous T cells engineered with an artificial receptor, able to recognize tumor antigens through an HLA-independent mechanism. We will review data on safety and efficacy outcomes with CAR T cell therapy in lymphomas.
Multicenter trials evaluating three CAR T cell products targeting CD19 have shown that they are highly effective and induce durable remissions in a substantial proportion of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma (NHL). The most common toxicities were cytokine release syndrome and neurotoxicity.
Two anti-CD19 CAR T cell products were approved by the FDA for the treatment of patients with relapsed or refractory aggressive B cell NHL. Ongoing research is aimed at investigating their use in earlier lines of therapy and in other B cell lymphomas, improving CAR T cell efficacy and safety, and evaluating novel targets.
KeywordsCAR T cell therapy Lymphoma CD19 Axicabtagene ciloleucel Tisagenlecleucel
PS and SSN have coauthored the paper.
Compliance with Ethical Standards
Conflict of Interest
Paolo Strati declares that he has no conflict of interest. Sattva S. Neelapu has received research support from Kite/Gilead, Celgene, Cellectis, Poseida, Merck, Acerta, Karus, and Bristol-Myers Squibb and has served as a consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, CellMedica, and Merck.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.CrossRefGoogle Scholar
- 3.Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.CrossRefGoogle Scholar
- 10.Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245–56.CrossRefGoogle Scholar
- 14.Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.CrossRefGoogle Scholar
- 19.• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44 This article describes the outcomes of the phase II component of the ZUMA-1 study, which led to FDA approval of axi-cel in 2017, marketed as Yescarta®, for patients with relapsed or refractory large B cell lymphoma after at least two lines of systemic therapy.CrossRefGoogle Scholar
- 20.Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018.Google Scholar
- 21.• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B cell lymphoma. N Engl J Med. 2018; This publication details the results of the JULIET study, which has led to the approval of tisagenlecleucel in 2018, marketed as Kymriah®, for the treatment of patients with relapsed large B cell lymphoma (excluding primary mediastinal B cell lymphoma) after at least two lines of systemic therapy.Google Scholar
- 23.•• Borchmann PTC, Jäger U, McGuirk JP, Holte H, Waller EK, Jaglowski SM, et al. An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapse3d or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). EHA. 2018:S799 These are the most updated results of the TRANSCEND study; FDA approval of liso-cel is still pending.Google Scholar
- 24.Abramson JS, Siddiqi T, Palomba ML, Gordon LI, Lunning MA, Arnason JE, et al. High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration. J Clin Oncol. 2018;36(5_suppl):120–0.Google Scholar
- 25.• Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2018; Together with no. 28, these articles, authored by a multi-institutional multidisciplinary team, discuss the grading and management of CAR T cell–related toxicities.Google Scholar
- 28.• Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62 Together with no. 25, these articles, authored by a multi-institutional multidisciplinary team, discuss the grading and management of CAR T cell–related toxicities.CrossRefGoogle Scholar
- 35.Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2018.Google Scholar
- 44.Chu F WJ, Kuang SQ, Cheng X, Cao J, Liu J, Karri S, Reddy A, Neelapu SS. Targeting CAR T resistance due to CD19 loss with CD79b-specific CAR T cells in B-cell malignancies. ASH. 2018.Google Scholar